Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952391807> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2952391807 endingPage "414" @default.
- W2952391807 startingPage "414" @default.
- W2952391807 abstract "Background: Activating NOTCH1 mutations are present in approximately 60% of T-cell acute lymphoblastic leukemia (T-ALL) cases. Mutant NOTCH1 is strictly dependent on γ-secretase processing for activation thereby providing a strong rationale for the use of γ-secretase inhibitors (GSIs) as a therapeutic approach for T-ALL. However, available GSI's lead to severe “on-target” gastrointestinal tract, skin and thymus toxicity, limiting their therapeutic application and clinical translation. What is less appreciated is that the enzymatic activity of the γ-secretase complex reflects the combined activity of at least four different complexes. These complexes broadly differ by the inclusion of one of two Presenilin (PSEN) proteins: PSEN1 or PSEN2, providing an opportunity to target specific complexes whilst avoiding toxicity in otherwise healthy tissue. Aims: To determine whether subunit selective gamma secretase inhibition is an effective therapeutic strategy in T-cell acute lymphoblastic leukemia. Methods: RNA-seq analysis was undertaken on T-ALL cell lines and patient samples. To generate mice carrying a Psen1 deletion in all committed B and T cell progenitors, we crossed Psen1 conditional knockout mice with CD2Cre. To generate conditional inducible Psen1 knockout mice, we bred animals harboring the conditional Psen1 allele with Rosa26Cre-ERt2 mice. In vivo bone marrow transplant (BMT) assays were performed using isolated hematopoietic stem and progenitor (HSPCs) cells and transduced with mutant NOTCH1 (HD-mutant, delta PEST) retroviral vectors. T-ALL patient derived xenograft studies in NSG mice were treated daily with MRK-560 (30 μmol/kg) and leukemia burden assessed by bioluminescence and human CD45 staining. Gut toxicity was assessed by Periodic acid–Schiff (PAS) immunohistochemistry. Results: Here we show that PSEN1 is expressed significantly higher than PSEN2 in human T-ALL cell lines and primary T-ALL samples. Genetically, the conditional deletion of Psen1 in mice significantly decreased mutant NOTCH1 receptor processing but did not impair normal T-cell development. Furthermore, specific inducible deletion of Psen1 in a mutant NOTCH1-driven leukemia significantly reduced leukemia burden and increased overall survival in vivo. The significant decrease in leukemic burden identified through genetic loss of Psen1 then prompted us to investigate whether selective pharmacological PSEN1 inhibition would be a viable strategy for T-ALL treatment. To this end, we tested the PSEN1 selective inhibitor MRK-560, which has ∼100-fold selectivity over PSEN2, on four different T-ALL patient-derived xenograft samples with varying NOTCH pathway mutations. MRK-560 monotherapy treatment significantly decreased leukemia burden as measured by in vivo bioluminescence and human CD45 in the peripheral blood and significantly increased overall survival. Moreover, treatment with MRK-560 did not cause any pathological changes in the gastrointestinal architecture nor increased numbers of secretory goblet cells, assessed by Periodic Acid-Schiff (PAS) staining, even after 4 weeks of treatment. Summary/Conclusion: These results demonstrate that inhibition of Presenilin-1 is highly effective in decreasing leukemia whilst avoiding dose-limiting toxicities and that Presenilin-1 selective compounds provide a new therapeutic strategy for safe and effective targeting of T-ALL." @default.
- W2952391807 created "2019-06-27" @default.
- W2952391807 creator A5013539196 @default.
- W2952391807 creator A5017778499 @default.
- W2952391807 creator A5032561016 @default.
- W2952391807 creator A5050277803 @default.
- W2952391807 creator A5053679651 @default.
- W2952391807 creator A5054227897 @default.
- W2952391807 creator A5069220713 @default.
- W2952391807 creator A5069266145 @default.
- W2952391807 creator A5073581497 @default.
- W2952391807 creator A5083753020 @default.
- W2952391807 date "2019-06-01" @default.
- W2952391807 modified "2023-09-27" @default.
- W2952391807 title "PS918 CIRCRNA DEREGULATION IN B-CELL PEDIATRIC ACUTE LEUKEMIA: THE MLL RECOMBINOME AND BEYOND" @default.
- W2952391807 doi "https://doi.org/10.1097/01.hs9.0000561952.76629.d2" @default.
- W2952391807 hasPublicationYear "2019" @default.
- W2952391807 type Work @default.
- W2952391807 sameAs 2952391807 @default.
- W2952391807 citedByCount "1" @default.
- W2952391807 countsByYear W29523918072022 @default.
- W2952391807 crossrefType "journal-article" @default.
- W2952391807 hasAuthorship W2952391807A5013539196 @default.
- W2952391807 hasAuthorship W2952391807A5017778499 @default.
- W2952391807 hasAuthorship W2952391807A5032561016 @default.
- W2952391807 hasAuthorship W2952391807A5050277803 @default.
- W2952391807 hasAuthorship W2952391807A5053679651 @default.
- W2952391807 hasAuthorship W2952391807A5054227897 @default.
- W2952391807 hasAuthorship W2952391807A5069220713 @default.
- W2952391807 hasAuthorship W2952391807A5069266145 @default.
- W2952391807 hasAuthorship W2952391807A5073581497 @default.
- W2952391807 hasAuthorship W2952391807A5083753020 @default.
- W2952391807 hasBestOaLocation W29523918071 @default.
- W2952391807 hasConcept C104317684 @default.
- W2952391807 hasConcept C111335760 @default.
- W2952391807 hasConcept C127716648 @default.
- W2952391807 hasConcept C161997846 @default.
- W2952391807 hasConcept C164659718 @default.
- W2952391807 hasConcept C201750760 @default.
- W2952391807 hasConcept C203014093 @default.
- W2952391807 hasConcept C2778461978 @default.
- W2952391807 hasConcept C2780007613 @default.
- W2952391807 hasConcept C28328180 @default.
- W2952391807 hasConcept C502942594 @default.
- W2952391807 hasConcept C54009773 @default.
- W2952391807 hasConcept C54355233 @default.
- W2952391807 hasConcept C81885089 @default.
- W2952391807 hasConcept C86803240 @default.
- W2952391807 hasConcept C95444343 @default.
- W2952391807 hasConceptScore W2952391807C104317684 @default.
- W2952391807 hasConceptScore W2952391807C111335760 @default.
- W2952391807 hasConceptScore W2952391807C127716648 @default.
- W2952391807 hasConceptScore W2952391807C161997846 @default.
- W2952391807 hasConceptScore W2952391807C164659718 @default.
- W2952391807 hasConceptScore W2952391807C201750760 @default.
- W2952391807 hasConceptScore W2952391807C203014093 @default.
- W2952391807 hasConceptScore W2952391807C2778461978 @default.
- W2952391807 hasConceptScore W2952391807C2780007613 @default.
- W2952391807 hasConceptScore W2952391807C28328180 @default.
- W2952391807 hasConceptScore W2952391807C502942594 @default.
- W2952391807 hasConceptScore W2952391807C54009773 @default.
- W2952391807 hasConceptScore W2952391807C54355233 @default.
- W2952391807 hasConceptScore W2952391807C81885089 @default.
- W2952391807 hasConceptScore W2952391807C86803240 @default.
- W2952391807 hasConceptScore W2952391807C95444343 @default.
- W2952391807 hasIssue "S1" @default.
- W2952391807 hasLocation W29523918071 @default.
- W2952391807 hasLocation W29523918072 @default.
- W2952391807 hasOpenAccess W2952391807 @default.
- W2952391807 hasPrimaryLocation W29523918071 @default.
- W2952391807 hasRelatedWork W1535744337 @default.
- W2952391807 hasRelatedWork W2011495040 @default.
- W2952391807 hasRelatedWork W2017802236 @default.
- W2952391807 hasRelatedWork W2027927113 @default.
- W2952391807 hasRelatedWork W2033212823 @default.
- W2952391807 hasRelatedWork W2098835181 @default.
- W2952391807 hasRelatedWork W2564717365 @default.
- W2952391807 hasRelatedWork W2582799992 @default.
- W2952391807 hasRelatedWork W3029982150 @default.
- W2952391807 hasRelatedWork W1968377433 @default.
- W2952391807 hasVolume "3" @default.
- W2952391807 isParatext "false" @default.
- W2952391807 isRetracted "false" @default.
- W2952391807 magId "2952391807" @default.
- W2952391807 workType "article" @default.